Osborn Williams & Donohoe LLC trimmed its holdings in shares of Novartis AG (NYSE:NVS) by 3.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,416 shares of the company’s stock after selling 2,158 shares during the quarter. Osborn Williams & Donohoe LLC’s holdings in Novartis were worth $5,517,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in NVS. Truvestments Capital LLC acquired a new position in shares of Novartis during the 1st quarter worth approximately $25,000. Canton Hathaway LLC acquired a new position in shares of Novartis during the 1st quarter worth approximately $26,000. Harvest Group Wealth Management LLC acquired a new position in shares of Novartis during the 1st quarter worth approximately $27,000. Asset Dedication LLC raised its stake in shares of Novartis by 98.7% during the 2nd quarter. Asset Dedication LLC now owns 304 shares of the company’s stock worth $27,000 after buying an additional 151 shares during the period. Finally, Financial Gravity Wealth Inc. acquired a new position in shares of Novartis during the 1st quarter worth approximately $33,000. 11.85% of the stock is owned by institutional investors and hedge funds.
NYSE:NVS traded up $0.57 during trading hours on Wednesday, hitting $88.79. The company had a trading volume of 4,672,115 shares, compared to its average volume of 2,254,085. The company has a current ratio of 0.94, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The business’s 50-day moving average price is $91.59. The firm has a market capitalization of $202.08 billion, a P/E ratio of 17.44, a P/E/G ratio of 2.10 and a beta of 0.58. Novartis AG has a 1 year low of $71.33 and a 1 year high of $95.00.
Several brokerages have recently weighed in on NVS. Argus upped their target price on Novartis to $105.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. They noted that the move was a valuation call. JPMorgan Chase & Co. reissued a “sell” rating on shares of Novartis in a research note on Friday, July 5th. Zacks Investment Research downgraded Novartis from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company. in a research note on Friday, July 19th. Morgan Stanley downgraded Novartis from an “equal weight” rating to an “underweight” rating and increased their price objective for the company from $82.50 to $82.52 in a research note on Wednesday, April 10th. Finally, Guggenheim raised Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price objective for the company in a research note on Wednesday, April 24th. Four research analysts have rated the stock with a sell rating, five have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $90.63.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Read More: Why do analysts give a neutral rating?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.